Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The suppressed lymphocyte proliferative responses characteristic of
graft-versus-host disease
(
GVHD
) are due, in part, to production of nitric oxide (NO). In order to more fully elucidate the role of NO during
GVHD
, an NO synthesis inhibitor, aminoguanidine (AG), was administered to unirradiated (C57BL/6J X DBA/2J)F1 mice injected with 5 X 10(7) C57BL/6J splenocytes. Administration of AG resulTed in abrogation of the elevation in serum NO2- + NO3- levels characteristic of
GVHD
. A significantly increased percentage of splenocytes of host phenotype (H2b/d, B220+, and
THY1
.2+) and a significantly higher hematocrit value were detected in
GVHD
animals receiving AG therapy. Additionally, the Con A-induced proliferative response of splenocytes obtained from
GVHD
mice receiving AG therapy was increased compared with the responses of splenocytes from animals that did not receive AG therapy. Parameters not affected by AG therapy included NO synthesis by recovered peritoneal macrophages, donor antihost cytolytic activity in splenocyte populations, serum GM-CSF levels and long-term engraftment of donor cells. These data indicate that NO may play a role in the destruction of both lymphoid and erythroid host tissue as well as the reduced lymphoproliferative responses associated with the acute phase of
GVHD
.
...
PMID:Bystander injury of host lymphoid tissue during murine graft-verus-host disease is mediated by nitric oxide. 861 Mar 89